(AIRT) Adopts Stockholder Rights Plan with Stockholder Protections

Rights Plan Will Expire at 2015 Annual Meeting Unless Ratified by Stockholders; Does Not Apply to Qualifying Offer Made for All Shares that Treats All Shareholders Equally

MAIDEN, N.C., Dec. 15, 2014  — Air T, Inc. (Nasdaq Capital Market: AIRT) announced today that its Board of Directors (the “Board”) adopted a Rights Agreement, pursuant to which one preferred stock purchase right will be distributed as a dividend on each share of the Company’s common stock held of record as of the close of business on December 26, 2014 (the “Rights”).  Initially, the Rights will be represented by the Company’s common stock certificates, or by the registration of uncertificated shares of common stock in the Company’s share register, and will not be exercisable.

The Board adopted the Rights Agreement in response to what it believes are recent rapid accumulations of significant portions of the Company’s outstanding common stock.  It is intended to protect the Company and its stockholders from efforts to obtain control that are inconsistent with the best interests of the Company and its stockholders.  The Rights Agreement provides several recognized stockholder protections:

• expires at the 2015 annual meeting of stockholders unless the stockholders vote to approve the Rights Agreement at that meeting (in which case it will expire in three years);
• has procedures for exempting offers made for all shares of the Company that treat all stockholders equally, that result in the bidder owning a majority of the Company’s shares and require the offeror to promptly complete a second-step transaction in which all shares not purchased in the offer will be acquired at the same consideration per share paid in the offer;
• guards against coercive tactics to gain control without paying all stockholders a premium for that control; and
• facilitates the ability of all shareholders to realize the full long-term value of their investment in the Company.

Under the Rights Agreement, with certain exceptions, if any person or group becomes the beneficial owner of 20% or more of the Company’s common stock, then each Right not beneficially owned by such beneficial owner will entitle its holder to purchase, at the Rights’ then-current exercise price, shares of the Company’s common stock having a market value of twice the Rights’ then-current exercise price.  In addition, with certain exceptions, if, after any person or group has become a beneficial owner of 20% or more of the Company’s common stock, the Company becomes involved in a merger or other business combination, each Right will entitle its holder (other than such 20% or more beneficial owner) to purchase, at the Rights’ then-current exercise price, common shares of the acquiring company having a value of twice the Rights’ then-current exercise price.

Further details about the Rights Agreement will be contained in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission by the Company.

About Air T
Air T, through its subsidiaries, provides overnight air freight service to the express delivery industry, manufactures and sells aircraft deicers and other special purpose industrial equipment, and provides ground support equipment and facilities maintenance to airlines.  Air T is one of the largest, small-aircraft air cargo operators in the United States.  Air T’s Mountain Air Cargo and CSA Air subsidiaries currently operate a fleet of single and twin-engine turbo-prop aircraft daily in the eastern half of the United States, Puerto Rico and the Caribbean Islands.  Air T’s Global Ground Support subsidiary manufactures deicing and other specialized military and industrial equipment and is one of the largest providers of deicers in the world.  The Global Aviation Services subsidiary provides ground support equipment and facilities maintenance to domestic airline customers.

(QTWW) Delivers Hydrogen Dispensing System to Linde for a Retail Fueling Station

LAKE FOREST, Calif., Dec 15, 2014  — Quantum Fuel Systems Technologies Worldwide, Inc. (NASDAQ: QTWW), a global leader in natural gas storage systems, integration and vehicle system technologies, in partnership with Linde North America, announces the first hydrogen dispensing system that measures hydrogen mass with connectivity to retail interface and user friendly payment features. The system was installed in West Sacramento and was unveiled at a grand opening hosted by the California Fuel Cell Partnership, Ramos Oil and Linde.

“For over a decade of development and prototyping, we have achieved the breakthrough of measuring and dispensing hydrogen fuel for commercial use in fuel-cell vehicles,” said Brian Olson, CEO of Quantum Technologies. “We are pleased with the results of our agreement with Linde and can expect further joint development efforts to the changing industry and standards,” continued Mr. Olson.

In partnership with Linde, Quantum has developed a highly specialized Hydrogen Dispenser system for 35 and 70 MPa service. For the first time, measuring the mass of hydrogen from a dispensing unit was successful and has received conditional approval for commercial service in California by the Department of Measurements and Standards. This is the first public accessible Hydrogen refueling station that has demonstrated SAE compliant fast fill performance with accurate mass flow measurement.

In addition to the development of dispensers, Quantum’s flag ship type IV tank, Q-Lite™, takes full advantage of maximizing gas and reducing storage weight not only experienced with CNG but also hydrogen.

About Quantum: Quantum Fuel Systems Technologies Worldwide, Inc. is a leader in the innovation, development and production of  hydrogen and natural gas fuel storage systems and the integration of vehicle system technologies including engine and vehicle control systems and drivetrains. Quantum produces one of the most innovative, advanced, and light‐weight hydrogen and compressed natural gas storage tanks in the world and supplies these tanks, in addition to fully‐integrated gas storage systems, to truck and automotive OEMs and aftermarket and OEM truck integrators. Quantum provides low emission and fast‐to‐market solutions to support the integration and production of natural gas fuel and storage systems, hybrid, fuel cell, and specialty vehicles, as well as hydrogen refueling stations. Quantum is headquartered in Lake Forest, California, and has operations and affiliations in the United States, Canada, and India.

About Linde: In the 2013 financial year, The Linde Group generated revenue of USD 23.1 bn (EUR 16.655 bn), making it the largest gases and engineering company in the world with approximately 63,500 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

Forward Looking Statements: This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this report, other than those that are historical, are forward looking statements and can generally be identified by words such as “may,” “could,” “will,” “should,” “assume,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “predict,” “estimate,” “forecast,” “outlook,” “potential,” or “continue,” or the negative of these terms, and other comparable terminology. Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements. Risk factors include the growth of the CNG market and acceptance of the Company’s product. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

More information about the products and services of Quantum can be found at http://www.qtww.com/ or you may contact:

Quantum Investor Relations
Phone: 949-399-4555
Email: ir@qtww.com

For more information, see The Linde Group online at www.linde.com.

Contact:
Amy Ficon
Linde corporate communications
908-771-1491
email: amy.ficon@linde.com

(CJJD) Completed the Acquisition of Hangzhou Sanhao Grand Pharmacy

HANGZHOU, China, Dec. 15, 2014  — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company” or “China Jo-Jo”), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, today announce that it has completed the acquisition of Hangzhou Sanhao Grand Pharmacy Chain Co., Ltd. (“Sanhao Drugstores”), a Hangzhou-based pharmacy chain with 11 stores.

Founded in 2006, Sanhao Drugstores is a well-known local drugstore chain and owns 11 drugstores in Hangzhou. Among the 11 stores, four have the qualification of “Designated Medical Institutions for Social Health Insurance (“SHI”),” and four others have passed the qualification tests. SHI Program is China’s national health insurance plan aimed to provide universal health insurance coverage to Chinese citizens. Only pharmacies with SHI qualification can serve SHI participants, thus acquiring SHI qualification would substantially enhance a pharmacy’s revenue and profitability. For example, the sales related to SHI accounted for about 55% of China Jo-Jo’s total sales in fiscal 2014.

The Company plans to relocate or remodel the majority of the acquired pharmacies in the upcoming months. After the restructuring of Sanhao Drugstores, the management expects it to generate about RMB 30 million (or $4.8 million) revenue in the calendar year of 2015.

Mr. Lei Liu, Chairman of the Company, stated, “The synergistic acquisition of Sanhao Drugstores will increase our total store count to over 60, from our current level of 51 drugstores. We also set our eyes on some key geographic locations in Hangzhou which allow us to expand our store penetration. We believe the investment will bring satisfactory economic benefits to our shareholders in the coming years.”About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and health care products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other health care products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

Contacts

China Jo-Jo Drugstores, Inc.
Ming Zhao
Chief Financial Officer
Tel: (561) 372-5555
Email: frank.zhao@jojodrugstores.com

(DAKP) Issues Open Letter To The Board Of Dakota Plains

Gratified to See Board Act to Exit Joint Ventures but Believes More Remains to be Done States Significant Additional Value Can Be Created with MLP Structure for the Pioneer Transloading Facility Calls on the Board to Take the Second Step of Creating Value and Initiate Strategic Alternatives Review Process

OLD GREENWICH, Conn., Dec. 15, 2014 — Lone Star Value Management, LLC (together with its affiliates, “Lone Star Value”), the largest shareholder of Dakota Plains Holdings, Inc. (NYSEMKT: DAKP) (“Dakota Plains” or the “Company”) with aggregate ownership of approximately 7.3% of the outstanding common stock, today issued an open letter to the Company’s Board of Directors.  The full text of the letter is included below:

December 15, 2014

Board of Directors
Dakota Plains Holdings, Inc.

Members of the Board:

Lone Star Value Investors, LP (“Lone Star Value”, “LSV”, “we” or “us”) currently owns 4,000,000 shares of Dakota Plains Holdings, Inc. (“Dakota Plains”, “DAKP” or the “Company”), making us DAKP’s largest shareholder.  At Lone Star Value, our goal is to invest in undervalued securities and engage with our portfolio companies to improve performance and maximize value for all shareholders.

We originally invested in the shares of Dakota Plains based on our valuation analysis which indicated that DAKP shares were materially undervalued versus our estimate of the Company’s net asset value per share and our belief that opportunities existed within the control of the Board and management to unlock value and close the valuation gap.  Our research on the Company’s Pioneer transloading facility uncovered a number of strategic strengths that, in our opinion, make Dakota Plains an attractive long-term investment, including:

• Strategic location in the core of the Bakken oil field; the core of the Bakken oil field has very low breakeven pricing levels ensuring continued growth in oil production volumes from the core area of the field leading to growing demand for access to DAKP’s transloading facility
• Oil production in North Dakota is expected to continue to exceed pipeline capacity creating long-term demand for crude-by-rail as an offtake solution
• Crude-by-rail is safe and cost-effective and will always be a key transportation mechanism for product to get to market from the Bakken
• Access to key rail line offtake systems and good relationships with railroads
• Pricing is based on a fixed fee per unit transported, not on commodity prices, making DAKP’s transloading asset perform more like a pipeline asset than an oil & gas asset
• In addition to exporting oil volumes out of the basin, DAKP’s transloading facility can also be used to import needed raw materials into the basin such as frac sand (as evidenced by DAKP’s JV with Unimin)

At Lone Star Value, whenever we discover an undervalued security, we examine why the security is undervalued and if the factors leading to the undervaluation are temporary and fixable.  When we originally invested in DAKP, we believed the Company’s complicated structure, whereby all assets were held in three different joint ventures, was causing a discount in DAKP’s stock price versus its underlying asset value per share.  DAKP’s multiple joint ventures presented a confusing picture for investors and unclear financial statements.  In addition to the Company’s core asset (the Pioneer transloading facility) being owned in a joint venture, the Company was also in two other non-core businesses via joint ventures: the Trucking business and the Marketing business.  Further, the Marketing business was once profitable, but began generating losses which created more volatility in DAKP’s earnings than is typical for a pipeline-type asset like the Pioneer transloading facility.

We were convinced that the best and critical first step to create value for all DAKP shareholders was unwinding the Company’s complicated joint venture structures and we sought to engage with the Board and management team to help the Company achieve this goal.  We invested significantly in DAKP, ultimately owning more than 5% of all outstanding shares and, upon your invitation, a representative of Lone Star Value joined the Dakota Plains Board.  We made it clear to you that in order for shareholder value to be maximized, DAKP needed to urgently become a pure play company owning 100% of a single asset — the strategic Pioneer transloading facility.

Accordingly, we were gratified to see Dakota Plains announce on November 10, 2014 that it had exited the Trucking joint venture as we suggested.  The Company also announced on that day the construction of a third storage tank at Pioneer allowing the facility to transport approximately 80,000 barrels of oil per day upon its completion in Q3 2015.  We were further pleased to see the Company announce on December 8, 2014 the unwinding of the Marketing joint venture and the purchase of its partner’s 50% share of the Transloading joint venture, thus exiting all joint ventures and owning 100% of the Pioneer transloading facility.

We have been disappointed, however, with the Board and management’s poor decision to wait so long to unwind its joint ventures and simplify the Company’s business structure.  This delay damaged shareholder value in our opinion based on our belief that the cost of unwinding of both the Marketing and Transloading joint ventures would have been lower had they been done sooner.  In addition, these value-creating steps were not undertaken until the Company was pressured to do so by shareholders.

We believe the Board needs to take further steps to maximize shareholder value.  For example, Dakota Plains’ Pioneer transloading facility would be far more attractive inside an MLP structure and an MLP is the ultimate natural owner of this asset similar to other pipelines and pipeline-type assets in the energy business.  Our analysis indicates that DAKP’s assets inside an MLP structure could be valued at $3.55-4.85 per share based on DAKP’s earnings potential by year-end 2015 once the tank 3 construction is complete and the facility is transporting 80,000 barrels of oil per day (see Exhibit A).  In addition, if further capital investment is made so that the Pioneer transloading facility can transport its full facility capacity of 160,000 barrels of oil per day, we believe DAKP’s potential future value in a few years could approach $7.70-10.20 per share inside an MLP structure (see Exhibit B).

We strongly believe that remaining a small cap C-corp will cause DAKP stock to continue to trade at a material discount to its intrinsic asset value.  An MLP structure is the optimal ownership structure for DAKP’s transloading asset and will generate the highest value for DAKP shareholders.  Given that Dakota Plains is now a pure-play Transloading company, we believe the time is right to initiate a Strategic Alternatives process whereby the Company would be sold in a competitive auction to the highest bidder, most likely to an MLP.

In summary, we are pleased to see the Board has finally made the strategic moves this year to convert Dakota Plains into a pure play business owning 100% of the Pioneer transloading facility.  As we have clearly stated in the past, we believe unwinding the Company’s joint venture structure was an important first step to generate value for shareholders.  However, we believe more remains to be done to fully capitalize on the value of the Company’s assets and strategic advantages.  In our view, the Pioneer transloading facility is more valuable to a larger company, particularly inside an MLP, and now is the right time to start the second step of creating value for shareholders by initiating a strategic alternatives process to sell the Company.

Sincerely,

Jeffrey E. Eberwein, Managing Member
Lone Star Value Management, LLC

About Lone Star Value Management:

Lone Star Value Management, LLC (“Lone Star Value”) is an investment firm that invests in undervalued securities and engages with its portfolio companies in a constructive way to help maximize value for all shareholders.  Lone Star Value was founded by Jeff Eberwein who was formerly a Portfolio Manager at Soros Fund Management and Viking Global Investors.  Lone Star Value is based in Old Greenwich, CT.

Jeffrey E. Eberwein
203.489.9500
je@lonestarvm.com

(SRNE) Strategic Investment By And Collaboration With Nantworks Founder

SAN DIEGO, Dec. 15, 2014  — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong.

Under the terms of the agreement, NantWorks and Sorrento will establish a global strategic collaboration to jointly develop next generation immunotherapies for the treatment of cancer and auto-immune diseases. NantWorks, through a subsidiary, and Sorrento intend to establish the first joint venture – “The Immunotherapy Antibody JV” – as an independent biotechnology company with $20 million initial joint funding. As part of a strategic investment, Dr. Soon-Shiong’s affiliated entity will acquire a 19.9% equity stake in Sorrento by purchasing common stock priced at $5.80 per share, Sorrento’s closing sale price on Friday, December 12, 2014. In addition, Sorrento granted the purchaser a 3-year warrant to purchase 1,724,138 shares of common stock at an exercise price of $5.80 per share.

The Immunotherapy Antibody JV will focus on accelerating the development of multiple immuno-oncology monoclonal antibodies (mAbs) for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4 mAbs, and other immune-check point antibodies as well as antibody drug conjugates (ADCs) and bispecific antibodies. The immuno-oncology field has emerged as the one of most exciting and fastest developing pharmaceutical market. Immunomodulatory antibodies help the cancer patient’s own immune system to fight the disease and are being developed for the treatment of a number of solid tumors. They have demonstrated therapeutic potential in difficult-to-treat cancers, such as metastatic melanoma and non-small cell lung cancer (NSCLC). A recent forecast by Citigroup predicts this market to become the biggest blockbuster drug class in history with potential sales of up to $35 billion a year over the next 10 years.

“We are extremely pleased to be working with Dr. Patrick-Soon Shiong and NantWorks. The investment into Sorrento and future formation of the JV with NantWorks further validate our G-MAB antibody technology and underscore Sorrento’s commitment to seeking strategic alliances in bringing its diverse portfolio of fully human monoclonal antibodies, ADCs, and bispecific antibodies into the clinic,” said Dr. Henry Ji, President and CEO of Sorrento. “Our innovative collaboration will unite Sorrento’s capability to develop complex biologics with NantWorks proprietary genomic and personalized medicine technologies. We share NantWorks’ enthusiasm for the potential of our JV to produce a pipeline of immuno-oncology products to address unmet needs of cancer treatment.”

“Combining NantWorks’ cutting edge expertise in genomic and molecular profiling of cancer patients and Sorrento’s industry-leading G-MAB antibody technology, we believe will enable us to develop multiple novel therapies for malignant disorders where there is currently a significant unmet need. Through this partnership, it is our goal to provide relief for millions of people who today have limited treatment options. This will be a model relationship aligned to accelerate development and production of novel cancer immunotherapies. We look forward to working closely with Sorrento’s team,” said Dr. Patrick Soon-Shiong, CEO and Founder of NantWorks.

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobile, NantMedia, NantOmics, NantBioScience, NantBioCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure.

The core mission of NantWorks is convergence: to develop and deliver a diverse range of
technologies that accelerates innovation, broaden the scope of scientific discovery, enhance
groundbreaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics.

About Sorrento Therapeutics, Inc. 

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq™, the next-generation nanoparticle paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated ADC platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, and ADCs.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about its Cynviloq registrational trial; and the advances made in developing RTX and human monoclonal antibodies, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

(FLXN) Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., Dec. 12, 2014  — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of its underwritten public offering of 5,040,000 shares of common stock at a price to the public of $17.00 per share. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.

BMO Capital Markets Corp. and RBC Capital Markets, LLC are acting as joint book-running managers. Needham & Company, LLC is acting as lead manager and Janney Montgomery Scott and Summer Street Research Partners are acting as co-managers.

Registration statements relating to the shares to be sold in the offering have become effective. The offering is being made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained from BMO Capital Markets Corp., 3 Times Square, 27th Floor, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com; or from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281; Attention: Equity Syndicate Department, Telephone: (877) 822-4089, Fax: (212) 428-6260.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Flexion’s securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company’s lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including expectations regarding the completion and timing of Flexion’s proposed public offering, are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described in Flexion’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Flexion’s Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC. You are encouraged to read Flexion’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and Flexion undertakes no obligation to update or revise any of the statements.

CONTACT: Media Contact
         Jamie Lacey-Moreira
         PressComm PR, LLC
         T: 410-299-3310
         jamielacey@presscommpr.com

         Corporate Contact
         Lisa Davidson, MBA
         Vice President, Finance and Administration
         Flexion Therapeutics, Inc.
         T: 781-305-7765
         ldavidson@flexiontherapeutics.com

(CISG) to Expand New Share Issue to Employees

GUANGZHOU, China, Dec. 12, 2014  — CNinsure Inc. (“CNinsure” or the “Company”) (Nasdaq:CISG), a leading independent insurance intermediary company in China, today announced that it has obtained approval from the Board of Directors to increase the new share issue to employees from up to 100,000,000 ordinary shares to 150,000,000 ordinary shares, representing approximately 15% of the Company’s current total outstanding share capital. The purchase price for the 100,000,000 ordinary shares is $0.27 per ordinary share or $5.4 per ADS, while that for the additional 50,000,000 ordinary shares is $0.29 per ordinary share or $5.8 per ADS, both of which are the average closing prices for the 20 trading days prior to the board approvals. Completion of the share issuances to the employees is subject to customary closing conditions.

“The new share issue was enthusiastically received by our employees, as reflected by the significant oversubscription. Therefore, we have decided to expand the size of the new share issue to meet the excess demand.” Mr. Chunlin Wang, the chief executive officer of CNinsure commented, “the strong demand shows a strong vote of confidence in the Company. We reaffirm our commitment to delivering long term sustainable growth for the benefit of all our shareholders.”

About CNinsure Inc.

CNinsure is a leading independent intermediary company operating in China. CNinsure’s distribution network reaches many of China’s most economically developed regions and affluent cities. The Company distributes a wide variety of property and casualty and life insurance products underwritten by domestic and foreign insurance companies operating in China, and provides insurance claims adjusting as well as other insurance-related services.

Forward-looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about CNinsure and the industry. Potential risks and uncertainties include, but are not limited to, those relating to CNinsure’s limited operating history, especially its limited experience in selling life insurance products, its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the evolving regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, and macroeconomic conditions in China and their potential impact on the sales of insurance products. All information provided in this press release is as of the date hereof, and CNinsure undertakes no obligation to update any forward-looking statements. Although CNinsure believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by CNinsure is included in CNinsure’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

CONTACT: For more information, please contact:
         Oasis Qiu
         Investor Relations Manager
         Tel: +86 (20) 6122-2731
         Email: qiusr@cninsure.net

(NAVB) Data Supporting Potential for Breakthrough with Manocept™ in Immunotherapy

Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), is pleased to present at a conference data generated by independent academic collaborators that it believes represent a pathway to a potential major scientific breakthrough in disease therapy, and more specifically, immunotherapy. Data will be presented to members of the scientific and investment communities both live in New York City and via webinar (details below).

Data will be presented that demonstrates that the Manocept™ backbone of tilmanocept, a component of an FDA-approved diagnostic agent, when attached to selected active therapeutic agents, can modulate over-active macrophages in clinically meaningful ways. To date, immunotherapy targeting the innate immune system has been limited to selectively blocking certain of the chemokines and cytokines produced by over-active macrophages. As a result of the high affinity of the Manocept platform compounds to CD206, which is only found in activated macrophage stages, one can now target the cell directly and modulate all of the activities of the overactive cell. This breakthrough has potential implications for radically new approaches to treatment in a broad array of diseases including infectious diseases, cancer, cardiovascular, autoimmune and central nervous system diseases.

Presenting at the webinar will be Frederick O. Cope, Ph.D., who will provide the technology overview covering the basic aspects of tilmanocept interactions with macrophages. Dr. Cope will also present data on the tuberculosis/macrophage relationships and the tilmanocept/CD206 relationship in the pathology of tuberculosis, as well as findings in rheumatoid arthritis. These studies have been generated in collaboration with researchers at The Ohio State University.

In the area of Kaposi’s sarcoma (KS), Michael McGrath, M.D., Ph.D., Professor, University of California, San Francisco, School of Medicine, will cover work done with tilmanocept in KS, HIV, and HVC.

Lastly, Steven Grinspoon, M.D., Professor of Medicine at Harvard Medical School, will discuss the ongoing work with vulnerable plaque and atherosclerosis and the role of CD206, macrophages and tilmanocept’s potential interactions in this pathology.

“We are humbled to be entrusted with this scientific breakthrough that has the potential to help so many patients. Our priority is to develop additional data in order to advance products utilizing this technology into clinical testing and then to the market. We are fortunate that we already have an FDA-approved indication with this technology as a diagnostic. As a result, we believe we have addressed many of the key commercialization issues for the technology and can now focus on the individual therapeutic applications. We are in the process of creating a Scientific Advisory Board of leading macrophage-focused immunologists as well as therapeutic area experts to assist us in prioritization within major disease categories,” said Navidea director Michael M. Goldberg, M.D., who is leading Navidea’s Macrophage Therapeutics efforts.

The conference and webinar will be held at 10:00 am (EST) this coming Monday, December 15^th, at 109 West 39th Street, New York, NY 10019.

The conference will also be available streaming online via webinar at: https://www3.gotomeeting.com/register/264506806, or by dialing Toll-free: 1 866 952 8437, Access Code: 622 843 441

About Macrophage Therapeutics

Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc., is developing new therapeutics based on its proprietary CD206 targeting technology platform. This will represent a new paradigm in the treatment of disease. Depending on the active agent(s) attached to the Manocept™ backbone as well as other core molecule permutations, it may be possible to approach immunotherapy in a completely novel manner. This approach has the potential to provide for management and modification of diseases that include the immediate involvement of macrophages, the biological products of macrophages, or the effective impact of macrophages or their progenitor and/or daughter elements. Thus, Macrophage Therapeutics’ Manocept platform is designed to specifically address a key element, macrophage interactions, in the natural progression of clinically significant diseases that impact the lives of patients around the globe.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

(ONTY) Exclusive License Agreement With Array BioPharma for ONT-380

SEATTLE, Dec. 12, 2014  — Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.

As part of the agreement, Oncothyreon will pay Array $20 million as an upfront fee. In addition, Oncothyreon will pay Array a significant portion of any payments received from sublicensing ONT-380 rights. If Oncothyreon is acquired within three years of the effective date of the current agreement, Array will be eligible for up to $280 million in commercial milestone payments. Array is also entitled to receive up to a double-digit royalty based on net sales of ONT-380.

“We are encouraged by the positive preliminary evidence of efficacy and tolerability seen in patients with advanced metastatic breast cancer in our ongoing Phase 1b trials of ONT-380, as will be reported today at the San Antonio Breast Cancer Symposium,” said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. “We are pleased, therefore, to obtain the exclusive rights to develop and commercialize ONT-380.”

About ONT-380

ONT-380 is an orally active, reversible and selective HER2 inhibitor invented at Array. In multiple preclinical tumor models, ONT-380 was well tolerated and demonstrated significant dose-related tumor growth inhibition that was superior to Herceptin® (trastuzumab) and Tykerb® (lapatinib). Additionally, in these models, ONT-380 demonstrated synergistic or additive tumor growth inhibition when dosed in combination with the standard-of-care therapeutics Herceptin or Taxotere® (docetaxel). ONT-380 has also demonstrated superior activity, based on overall survival, compared to Tykerb® and to the investigational drug, neratinib, in an intracranial HER2 positive breast cancer xenograft model.

A Phase 1 trial of ONT-380, with both dose-escalation and expansion components, has been completed in 50 patients, 43 of whom had HER2 positive metastatic breast cancer. All HER2 positive breast cancer patients had progressed on a Herceptin-containing regimen. In addition, over 80 percent had been treated with Tykerb, with many having progressed on therapy. In this study, ONT-380 demonstrated an acceptable safety profile; treatment-related adverse events were primarily Grade 1. Because ONT-380 is selective for HER2 and does not inhibit EGFR, there was a low incidence and severity of treatment-related diarrhea, rash and fatigue. Additionally, there were no treatment-related cardiac events or Grade 4 treatment-related adverse events reported. Twenty-two HER2 positive breast cancer patients with measurable disease were treated with ONT-380 at doses greater than or equal to 600 mg BID. In this heavily pretreated patient population, there was a clinical benefit rate (partial response [n = 3] plus stable disease for at least 6 months [n = 3]) of 27 percent.

Oncothyreon is currently conducting two Phase 1b trials of ONT-380 in combination with other agents. The first trial (ClinicalTrials.gov Identifier NCT02025192) is a parallel dose-escalation study of ONT-380 in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients who have been previously treated with Herceptin and Kadcyla® (ado-trastuzumab emtansine or TDM-1) for metastatic breast cancer.  The second trial (ClinicalTrials.gov Identifier NCT01983501) is a dose-escalation study of ONT-380 in combination with Kadcyla in patients who have been previously treated with Herceptin and a taxane for metastatic breast cancer. Preliminary data from both trials will be presented today at the San Antonio Breast Cancer Symposium and are summarized in an accompanying press release.

About Oncothyreon

Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology, and potentially certain rare diseases, using our recently acquired protocell technology. For more information, visit www.oncothyreon.com.

Oncothyreon Forward-Looking Statements

In order to provide Oncothyreon’s investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Oncothyreon’s expectations regarding clinical development activities.

Forward-looking statements involve risks and uncertainties related to Oncothyreon’s business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Oncothyreon’s actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of our product candidates, and the indications for which our product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. Although Oncothyreon believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Oncothyreon’s risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

CONTACT: Oncothyreon Investor and Media Relations Contact:	

         Julie Rathbun
         Rathbun Communications
         206-769-9219
         ir@oncothyreon.com

(CCXI) Positive Results in Phase II Diabetic Nephropathy Trial CCR2 Inhibitor CCX140

Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks

Improved Estimated Glomerular Filtration Rate Profile versus Standard of Care

Favorable Safety Profile for CCX140

Company to Host Conference Call and Webcast Today at 8:30a.m. ET

MOUNTAIN VIEW, Calif., Dec. 12, 2014  — ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2.

The trial met its primary endpoint by demonstrating that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen (SOC) of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor II blocker (ARB) treatment resulted in a statistically significant (p=0.0148) reduction in urinary albumin creatinine ratio (UACR), beyond that achieved with SOC alone. High UACR is known to predict poor renal outcome. The maximum treatment effect (24 percent reduction) was reached at 12 weeks, and sustained reduction in albuminuria induced by CCX140 relative to SOC alone was observed over the full year, i.e., UACR at each one of the 10 time points over the 52-week treatment period in the patients who received 5 mg CCX140 continuously for 52 weeks, were below those of the SOC alone group. A dose of 10 mg CCX140 per day did not provide more improvement in albuminuria as compared to the 5 mg dose.

In addition, estimated glomerular filtration rate (eGFR) changes were assessed. Measuring eGFR is important in assessing long-term kidney function (over many months to years), and provides the basis for Phase III clinical trial registration endpoints. Numerous clinical trials with the current SOC (ACE inhibitors and ARBs) show that these attenuate the slope of decline of eGFR, and that this translates into a beneficial effect on clinical outcome parameters such as time to dialysis, with chronic multi-year treatment. Treatment with CCX140 improved the eGFR profile. Initial analysis showed that after an acute effect in eGFR in the CCX140 treatment groups in the first 12 weeks, there was a sustained attenuation in the slope of annual decline in eGFR. Such eGFR profiles have been associated with successful long-term clinical benefit in kidney outcomes with approved diabetic nephropathy drugs. The treatment group receiving 5 mg of CCX140 in addition to SOC showed an attenuated annual slope decline of 1.3 mL/min/1.73 m², compared to SOC alone group, 2.3 mL/min/1.73 m². The magnitude of slope improvement seen for CCX140 is consistent with drugs that have been previously approved for diabetic nephropathy.

CCX140 did not affect systemic blood pressure, suggesting that the beneficial effect of CCX140 is mediated locally in the kidney micro-environment, possibly through a beneficial reduction in renal inflammation. CCX140 appeared to be well tolerated with a low overall dropout rate over the 52-week treatment period (10 percent). No safety issues were observed that would prevent further clinical development of CCX140 in diabetic nephropathy.

“These positive data suggest that treatment with CCX140 may result in clinically meaningful improvements in kidney function when added to standard of care in patients with chronic kidney disease,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer, ChemoCentryx. “Given the positive improvements in albuminuria and eGFR observed in this clinical trial, we believe we have an effective dose of CCX140 to take forward into a Phase III clinical trial in diabetic nephropathy, and that we are well positioned to advance partnering discussions as well as an end of Phase II meeting with the FDA.”

“Even with optimal current care, the residual risk in diabetic nephropathy patients for further decrease in renal function is still extremely high,” said Prof. Dick de Zeeuw, M.D., Ph.D., in the Department of Clinical Pharmacy and Pharmacology at the University Medical Center in Groningen, The Netherlands. “The search for new drugs that add to standard of care ACE inhibitor and ARB treatment is therefore of utmost importance. To date, no great successes of new drugs on surrogates like blood pressure, albuminuria, or estimated glomerular filtration rate have been reported. These robust results with CCX140, in this context, are extremely relevant and promising, particularly if translated into preservation of renal function. CCX140 should definitely be tested in a Phase III trial.”

The Company plans to present the full results of this clinical trial at upcoming medical meetings.

Study Design

The objectives of the Phase II study, which took place at more than 90 sites across six European countries, were to determine the safety, tolerability and signs of clinical effect of CCX140 in patients with diabetic nephropathy. CCX140 was studied in a randomized, double-blind, placebo controlled clinical trial in 332 patients with residual albuminuria, despite having received an ACE inhibitor or ARB for at least eight weeks prior to screening for this trial. The original protocol had a 12-week treatment period that was extended to 52 weeks by protocol amendment. Of the 332 patients enrolled in the study initially, 102 patients were ineligible to re-enroll after the protocol amendment approval due to the length of time off treatment. As such 196 patients participated in the study extension to receive treatment for 52 weeks. The primary safety objective was evaluation of the safety profile of CCX140 based on the incidence of adverse events. The primary efficacy endpoint was the evaluation of the effect of CCX140 treatment over 52 weeks on first morning urinary albumin:creatinine ratio. Secondary objectives included evaluation of the effect of CCX140 on eGFR and HbA1c. At baseline, the mean age of the study population was 63 years, the median duration of type 2 diabetes was 14.5 years and the median duration of nephropathy was 3.3 years. The baseline mean urinary ACR for the population overall was 636 mg/g creatinine and baseline mean eGFR was 63 mL/min/1.73 m². Baseline mean arterial blood pressure was 98 mm Hg.

About Diabetic Nephropathy

Diabetic nephropathy is a progressive kidney disease characterized primarily by proteinuria in patients with diabetes. Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in the United States, resulting in the need for dialysis or kidney transplantation. Of the 26 million patients with chronic kidney disease, approximately 35 percent of those are patients with diabetes.

About CCX140

CCX140 is an inhibitor of the chemokine receptor known as CCR2. CCR2 is found on subsets of monocytes and macrophages, which are cells of the immune system believed to play an important role in inflammatory processes. Blocking CCR2 is intended to reduce the abnormal monocyte- and macrophage-driven inflammatory response implicated in renal diseases such as diabetic nephropathy. CCR2 may also have a direct role in the function of other specialized cells in the kidney, where its inhibition would correlate with a positive therapeutic effect.

Conference Call Information

The Company will host a conference call and webcast today, December 12, 2014 at 8:30 a.m. Eastern Time to discuss Phase II trial results and to answer questions. The live event will be accessible on the ChemoCentryx website beginning at 8:30 a.m. ET at www.ChemoCentryx.com, under the Investors section, or by calling 877-303-8028 (domestic) or 760-536-5167 (international). The conference ID number is 52903154

An archived webcast will be accessible via the Investors section of the Company’s website at www.ChemoCentryx.com. The webcast will remain available for thirty (30) days following the live call.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvements in kidney function in patients with diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX872, a next generation CCR2 inhibitor, currently in Phase I clinical development, CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Forward-Looking Statements

ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential” or “continue” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include statements regarding whether CCX140 will be shown to be effective in Phase III clinical trials or obtain regulatory approval or the speed with which such approval might be obtained and statements regarding the ability of ChemoCentryx to successfully partner the development of CCX140. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in ChemoCentryx’s periodic reports filed with the SEC, including ChemoCentryx’s Quarterly Report on Form 10-Q filed with the SEC November 6, 2014 and its other reports which are available from the SEC’s website (www.sec.gov) and on ChemoCentryx’s website (www.chemocentryx.com) under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Source: ChemoCentryx (CCXI-G)

CONTACT: Susan M. Kanaya
         Senior Vice President, Finance and
         Chief Financial Officer or
         Markus J. Cappel, Ph.D.
         Chief Business Officer
         650.210.2900
         investor@chemocentryx.com

         Media:
         Denise Powell
         510.703.9491
         denise@redhousecomms.com

         Investors:
         Angeli Kolhatkar
         Burns McClellan
         212.213.0006
         akolhatkar@burnsmc.com

(DAKP) Update on Pioneer Terminal Expansion and Operations, 2015 Guidance

Tank Storage Expansion Underway on Schedule and Fully Funded New Contracts Increase Throughput to 55,000 Barrels Per Day Beginning in January 2015 Company Provides Full Year 2015 Adjusted EBITDA Guidance of $23.4 million

Dakota Plains Holdings, Inc. (“Dakota Plains” or “the Company”) (NYSE MKT:DAKP) today provided an update on its operations and made several disclosures related to its growth. Highlights are as follows:

• The storage tank expansion project currently underway successfully achieved its winter shut-down point with construction expected to resume in the spring of 2015; the project is on schedule and fully funded. In addition, a new service agreement with an existing client enables increasing the throughput of the Pioneer Terminal to 55,000 barrels per day from January 2015.
• Canadian Pacific has pledged an expanded rail service to underpin the forecast increases in throughput at Pioneer.
• For 2015 the Company provides an annualized guidance that includes an average daily throughput of 57,500 barrels per day and an adjusted EBITDA of $23.4 million.

Craig McKenzie, Chairman and Chief Executive Officer of Dakota Plains, said, “The transaction to buy out our joint venture partner delivers significant value to stockholders as we grow the Pioneer Terminal. The Company is now simpler in its structure and business segments, is stronger in terms of balance sheet and income generation, is no longer exposed to direct commodity pricing risk, and is more flexible than in the past to meet our customers’ needs in logistical services. Based on significant levels of increased interest, we are considering further expansion of the Pioneer Terminal beyond 80,000 barrels per day.”

McKenzie added, “We are encouraged to see significant growth opportunities even during the current low oil price environment. I believe this is a tribute to our competitive advantage as a centrally located, reliable, and cost efficient rail terminal that plays an important role in transporting Bakken and Three Forks oil to market.”

Conference Call

The company will host a conference call on Friday, December 12 at 11:00 am ET to discuss its operational and financial updates with the investment community.

Participants should dial 1-888-256-9132 if calling within the United States or 1-913-312-0653 if calling internationally. A replay will be available until December 19, 2014 and can be accessed by dialing 1-877-870-5176 if calling within the United States or 1-858-384-5517 if calling internationally. Please use passcode 3580581 to access the replay.

In addition, the call will be webcast and will be available on the Company’s website at www.dakotaplains.com or by visiting http://public.viavid.com/index.php?id=112283.

A form 8K has been filed containing a slide presentation that management will reference during the call. The presentation is available on our website at http://dakotaplains.com/investor/presentations/

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP measure. A reconciliation of this measure to its most directly comparable GAAP measure is included in the accompanying financial tables found later in this release. Management believes the use of this non-GAAP financial measure provides useful information to investors to gain an overall understanding of current financial performance. Specifically, management believes the non-GAAP results included herein provide useful information to both management and investors by excluding certain expenses and gains and losses on the extinguishment of debt that management believes are not indicative of Dakota Plains’ core operating results. In addition, this non-GAAP financial measure is used by management for budgeting and forecasting as well as subsequently measuring Dakota Plains’ performance, and management believes it is providing investors with a financial measure that most closely aligns to its internal measurement processes.

About Dakota Plains Holdings, Inc.

Dakota Plains Holdings, Inc. is an integrated midstream energy company operating the Pioneer Terminal transloading facility. The Pioneer Terminal is centrally located in Mountrail County, North Dakota, for Bakken and Three Forks related Energy & Production activity. For more information please visit the corporate website at: www.dakotaplains.com.

Forward Looking Statements

Statements made by representatives of Dakota Plains Holdings, Inc. (“Dakota Plains” or the “Company”) during the course of this press release that are not historical facts, are forward-looking statements. These statements are based on certain assumptions and expectations made by the Company which reflect management’s experience, estimates and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or anticipated in the forward-looking statements. These include risks relating to global economics or politics, our ability to obtain additional capital needed to implement our business plan, minimal operating history, loss of key personnel, lack of business diversification, reliance on strategic, third-party relationships, financial performance and results, prices and demand for oil, our ability to make acquisitions on economically acceptable terms, and other factors described from time to time in the Company’s periodic reports filed with the SEC that could cause actual results to differ materially from those anticipated or implied in the forward-looking statements. Dakota Plains undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information or future events.

(ALXA) Diario Medico Names ADASUVE® in its “Best Ideas of 2014”

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Dec. 11, 2014  — Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that the Spanish-based publication Diario Medico included ADASUVE^® (Staccato^® loxapine) in its “Best Ideas of 2014” awards.  The Best Ideas awards by Diario Medico acknowledge the daily work of persons, institutions or enterprises that contributed to the improvement of medicine, healthcare, and public health during the previous year.  Ferrer is Alexza’s commercial partner for ADASUVE in the European Union, Latin America, and the Commonwealth of Independent States countries.

“This award recognizes the innovation that is ADASUVE and its contribution to the improvement in the quality of life of the patients suffering from bipolar disorder and schizophrenia,” said Antoni Villaro, Chief Operating Officer of Ferrer.  “We continue to hear from doctors and nurses who are using ADASUVE that they are impressed with ADASUVE’s strong efficacy and rapid onset as well as its potential to change the practice in treating these patients.”

“The Diario Medico Best Idea award exemplifies the vision of our founder, Dr. Alejandro Zaffaroni.  He believed we could improve patient therapies with our Staccato^® technology, where drugs are quickly vaporized to deliver alternative therapeutic options for a variety of acute and intermittent conditions,” said Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals.  “We believe ADASUVE’s combination of an effective drug in our Staccato system can be a model for changing other suboptimal standard-of-care regimens.  Our primary focus in the near term remains supporting the global commercialization of ADASUVE, and we also look forward to building on the success of this first approved product and developing other product candidates in the coming years.”

About Staccato^®
Staccato technology is a novel form of inhaled drug delivery that is uniquely suited for conditions requiring speed of therapeutic effect, reliable dosing, and ease of use.  Staccato system single-dose device houses a heat package comprising a stainless steel substrate, which is coated with excipient-free drug – the system requires no excipients or pharmaceutical stabilizers.  With a single breath by the patient, the system rapidly actuates to form a drug aerosol of consistent sized particles between one and three microns.  At this size, the particles are rapidly absorbed in the deep lung, ensuring rapid uptake in the bloodstream and rapid onset of pharmacological effect.

About ADASUVE (Staccato loxapine)
ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product.  ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.  The EU marketing authorization for ADASUVE requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms.  It also requires that ADASUVE be administered only in a hospital setting under the supervision of a healthcare professional.  Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side effects, such as bronchospasm.

Alexza and Ferrer estimate that as many as 8 million adults in the EU suffer from schizophrenia or bipolar disorder¹.  Agitation is a common symptom for these patients², characterized by feelings of distress, anxiety, and loss of control.

The authorization for ADASUVE in the EU differs from that in the United States, with respect to the indication statement, dose regimen, available dose strengths, and risk mitigation and management plans.  For more information about ADASUVE, including the Summary of Product Characteristics and Patient Information Leaflet approved in the EU, please visit the EMA website.  For the full prescribing information including boxed warnings for the U.S., please visit www.adasuve.com.

About Ferrer
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona.  It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States.  In total, Ferrer’s human healthcare products are commercialized in more than 90 countries, through 27 international affiliates (including joint ventures) and 70 partners and distributors.

Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals.  Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors.  For more information, visit www.ferrer.com.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza’s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE is Alexza’s first commercial product, is based on the Staccato technology, and has been approved for sale by the U.S. Food and Drug Administration, the European Commission, and in several Latin American countries.

Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza’s commercial partner for ADASUVE in the U.S.  Ferrer is Alexza’s commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries.  For more information, visit www.alexza.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
This news release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and its partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company’s capital to support the Company’s operations, and the Company’s ability to raise additional funds and the potential terms of such potential financings. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

References:

1.   Wittchen H.U., et al., 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679.

2.   Alexza data on file (primary market research among caregivers of patients with schizophrenia (95% have agitation) and bipolar patients (87% have agitation).

(CLIR) Names Stephen E. Pirnat As Chief Executive Officer

SEATTLE, Dec. 11, 2014  — ClearSign Combustion Corporation (NASDAQ: CLIR) (“ClearSign”), an emerging leader in combustion and emissions control technology for industrial, commercial and utility markets, announced today that its Board of Directors has appointed Board member Stephen E. Pirnat as ClearSign’s Chairman and Chief Executive Officer, replacing Richard F. Rutkowski, who resigned his officer and director positions with ClearSign on December 10, 2014. Until Mr. Pirnat assumes office, James N. Harmon, ClearSign’s Chief Financial Officer, will act as interim President (principal executive officer).

Mr. Pirnat, who joined the ClearSign Board of Directors in November of 2011, has extensive experience in the energy supply and services sector, including as the former President and CEO of the John Zink Company, LLC, a subsidiary of Koch Industries and a global leader in the supply of combustion and environmental equipment to the refining, petrochemical, production/exploration and utility industries.

“Steve is a transformational leader with a proven track record of building shareholder value through the development and successful commercialization of innovative products and a focus on operational excellence,” said ClearSign Director, Scott Isaacson. “The board believes he is ideally suited to lead this next phase of ClearSign’s development as ClearSign continues its transition from a development phase into a product and customer focus. Steve’s experience makes him the ideal candidate to lead ClearSign forward.”

At John Zink, Mr. Pirnat oversaw a period of rapid growth both in revenue and profitability, driven by several new product innovations and multiple synergistic acquisitions.

“I am honored to have been asked by the Board to lead ClearSign into the next phase of its growth,” said Pirnat. “The opportunities for ClearSign’s game-changing technologies are immense, and I am very excited to be a part of it.”

Commenting on the transition, Scott Isaacson added, “On behalf of ClearSign and the Board, I want to express our heartfelt gratitude to Rick for his vision. From little more than a revolutionary idea when ClearSign was founded in 2008, through a period of rapid development of both technology and intellectual property, Rick’s efforts have enabled ClearSign to build a foundation upon which to grow.”

Mr. Pirnat was most recently Managing Director of Europe, the Middle East and African operations at Quest Integrity Group, a division of Team Industrial Services, a provider of asset integrity management and asset reliability solutions in the refinery, chemical, petrochemical, pipeline and power industries worldwide. From 2009 to 2011, he was President of Quest Integrated Inc., a technology incubator and boutique private equity firm. From 2000 to 2009, Mr. Pirnat served as President & CEO of the John Zink Company, LLC, a wholly owned subsidiary of Koch Industries and a worldwide leader in the supply of combustion and air pollution control equipment to the energy industry. Mr. Pirnat, a long-time executive with Ingersoll-Rand and Ingersoll-Dresser Corporation, went to John Zink from a previous post as President & CEO of Pangborn Corporation, a leading supplier of surface preparation equipment and associated services to the automotive and aircraft industries. Mr. Pirnat began his career as an applications engineer with the Pump and Condenser Group of Ingersoll-Rand, where he advanced through a variety of sales, marketing, engineering, and operational positions with that company and its successor, Ingersoll-Dresser. These positions included Vice President of Ingersoll-Rand’s Standard Products Division, Vice President of Marketing for Ingersoll-Dresser Pumps, President of Ingersoll-Dresser Pumps Canada Ltd., and Vice President & General Manager of Ingersoll-Rand Engineered Equipment Division. Mr. Pirnat received a BSc. in Mechanical Engineering from the New Jersey Institute of Technology.

Mr. Pirnat will be based at ClearSign headquarters in Seattle.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our Duplex™ Tile and Electrodynamic Combustion Control™ (ECC™) platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about ClearSign, please visit www.clearsign.com

Cautionary note on forward-looking statements

This press release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management’s belief, as well as assumptions made by, and information currently available to, management. While we believe that our expectations are based upon reasonable assumptions, there can be no assurances that our goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect our actual results and may cause results to differ materially from those expressed in forward-looking statements made by us or on our behalf. Some of these factors include the acceptance of existing and future products, the impact of competitive products and pricing, general business and economic conditions, and other factors detailed in our periodic reports filed with the SEC. We specifically disclaim any obligation to update or revise any forward-looking statement whether as a result of new information, future developments or otherwise.

(ABIO) Announces Activation of First Canadian Genetic-AF Clinical Trial Site

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the activation of the first GENETIC-AF clinical trial site in Canada. The site activation follows on the August 2014 acceptance by Health Canada of the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro^TM as a potential treatment for atrial fibrillation (AF). This site brings the total current number of active trial sites to thirty-three. ARCA plans to activate a total of approximately 60 clinical trial sites in the United States and Canada for the Phase 2B portion of the trial.

ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is now enrolling patients in the United States and Canada. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation.

Stuart Connolly, MD, Director of the Division of Cardiology at McMaster University in Hamilton, Ontario, Canada, and Co-Chairman of the GENETIC-AF Steering Committee, commented, “This trial is an innovative pharmacogenetic approach to evaluating the potential efficacy of bucindolol as a treatment for atrial fibrillation. Atrial fibrillation is a growing problem where current medical therapy does not provide adequate treatment, particularly in heart failure populations.”

Jeff Healey, MD and Country Principal Investigator, commented further, “Canadian health care and its clinical trial culture is ideally suited for a trial such as GENETIC-AF, which investigates a potential advance in the unmet need areas of atrial fibrillation prevention and/or rate control in a heart failure population. I hope the Canadian GENETIC-AF trial sites will contribute a substantial number of patients to this program to help advance a potential new treatment for patients at high risk for developing, or living with, atrial fibrillation.”

About Atrial Fibrillation (AF)

Atrial fibrillation, the most common sustained cardiac arrhythmia, is considered an epidemic cardiovascular disease and a major public health burden. The estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2014 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the U.S. in 2010 ranged from 2.7 million to 6.1 million people. Hospitalization rates for AF increased by 23% among US adults from 2000 to 2010 and hospitalizations account for the majority of the economic cost burden associated with AF.

AF is a disorder in which the normally regular and coordinated contraction pattern of the heart’s two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. These include toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. The Company believes there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients.

GENETIC-AF Clinical Trial

GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.

The AF indication for Gencaro was chosen based on clinical data from the previously conducted Phase 3 heart failure trial of 2,708 patients (the BEST trial). The Company believes data from the BEST trial indicate that Gencaro may have a genetically regulated effect in reducing or preventing AF, whereas the Company believes the therapeutic benefit of Toprol-XL does not appear to be enhanced in patients with this genotype. A retrospective analysis of data from the BEST trial shows that the entire cohort of patients in the BEST trial treated with Gencaro had a 41% reduction in the risk of new onset AF (time-to-event) compared to placebo (p = 0.0004). In the BEST DNA substudy, patients with the beta-1 389 arginine homozygous genotype experienced a 74% (p = 0.0003) reduction in risk of AF when receiving Gencaro, based on the same analysis.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro^TM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company’s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

(SPLS) Offers Expanded Me to We Collection

TORONTO, Dec. 10, 2014 – Staples Canada today announced the expansion of the Me to We product line, an assortment of exclusive products that make life-changing impacts in communities overseas, from providing access to education to clean water. Launched earlier this year with back-to-school supplies, the expanded Staples collection features mittens, scarves, toques and travel mugs to keep givers and receivers warm this season.

“Giving a gift always feels great,” said Steve Matyas, president of Staples Canada.  “But giving a gift that benefits others feels even better. Customers love the Me to We collection, and we’re pleased to be able to grow it just in time for the holiday season.”

All products come with a unique eight-digit code for buyers to track exactly where and how their purchase gives a life-changing gift. Customers can visit trackyourimpact.com to learn more about the impact of their particular purchase.

Within just five months of its original launch, the Me to We collection at Staples has already made positive strides in providing essentials for communities around the world. Highlights to date include:

• More than 40,000 pencils
• More than 115,000 lunches
• Some 10,000 trees planted
• Vitamins for more than 1,800 people
• 100 million litres of water

“There’s giving and then there’s giving exponentially,” said Roxanne Joyal, CEO at Me to We. “When you purchase gifts for you and your loved ones, Me to We products enhance the season’s glow while making life-changing impacts in communities overseas—essentially spreading the holiday spirit around the globe.  With the introduction of the Staples Me to We Holiday Collection we’re providing communities around the world with access to education and essential resources that help break the cycle of poverty.”

For information about the Me to We collection at Staples Canada, visit staples.ca/metowe or www.metowe.com.

For a complete list of featured Holiday products and gifts, visit staples.ca/holiday.

About Me to We
Me to We is an innovative social enterprise that offers socially conscious products and services, including socially conscious and environmentally friendly clothes and accessories, as well as life-changing international volunteer trips, leadership training programs and materials, an inspirational speakers bureau, and books which address issues of positive social change. In addition, half of Me to We’s net profit is donated to Free The Children, while the other half is reinvested to grow the enterprise and its social mission. Visit www.metowe.com for more information.

About Staples Canada
Staples makes it easy to make more happen with more products and more ways to shop. Through its world-class retail, online and delivery capabilities, Staples lets customers shop however and whenever they want, whether it’s in-store, online or on mobile devices. Staples offers more products than ever, such as technology, facilities and breakroom supplies, furniture, safety supplies, medical supplies, Copy and Print services and, of course, school supplies. Headquartered outside Boston with Canadian regional offices in Toronto, Laval and Vancouver, Staples operates throughout North and South America, Europe, Asia, Australia and New Zealand. More information about Staples (SPLS) is available at staples.ca.

SOURCE Staples Canada Inc.

Image with caption: “Me to We Mittens. Every Me to We purchase makes a positive impact in a Free The Children community overseas. To see where in the world you made a difference, enter the code found on your product at TrackYourImpact.com (CNW Group/Staples Canada Inc.)”. Image available at: http://photos.newswire.ca/images/download/20141211_C5762_PHOTO_EN_9347.jpg

Media contacts: Jay Reyes, Torchia Communications, 416-341-9929 Ext. 222, jay@torchiacom.com; Alessandra Saccal, Staples Canada, 905-737-1147 Ext.2363, alessandra.saccal@staples.caCopyright CNW Group 2014

(DXM) Organizational Restructuring Yielding up to $150M in Annual Expense Savings

Dex Media, Inc. (NASDAQ:DXM), one of the largest national providers of social, local and mobile marketing solutions to local businesses, today announced sweeping changes designed to reorganize and refocus the company. These changes will result in run-rate annual structural savings estimated between $130 million to $150 million. The savings will ramp up over the first eight months of 2015, with $90 million to $110 million to be realized within the year. One-time cost to achieve is expected to be in the range of $70 million to $100 million, the majority expensed by the end of 2015. Management also expects to identify further expense reductions in 2016 and beyond.

With the cost savings and sales enhancement changes implemented today, the company expects to begin deleveragingwithin 2016.¹ All areas of the company are affected by the changes. Major strategic changes impacting the cost structure include the following:

• Launch of the virtual sales office. Sales reps will be equipped to perform all work with wireless technology, without need for a physical sales office, so they can spend more time with clients. This will enable elimination of all field sales offices.
• Automation of the sales process, enabling a paperless environment where orders will flow through to fulfillment untouched by human hands.
• Integration of systems to eliminate duplication left over since the merger of Dex One and SuperMedia. This will enable streamlining of product portfolios and a material reduction in personnel.
• Variabilizing the print cost structure to enable directory costs to change in lock step with decreases in consumer usage, in addition to the structural cost savings mentioned above.

Today’s changes included planned workforce reductions and job reassignments through 2015 that will impact approximately 1,000 employees or 25% of the company’s employee base, including 350 field sales representatives. The company also de-layered its sales organization by eliminating a layer of management and allowing these experienced sales professionals to return to the field. Additional reductions occurred in the company’s administrative, sales support, field marketing, publishing, distribution, and technology organizations.

In addition to reductions in cost, the company announced a number of revenue enhancement measures. These upgrades include product simplifications enabling a more intuitive client sales call and more satisfying client experience; the introduction of new sales tools, automation of the sales presentation and sales process; enhanced Internet yellow pages (IYP) products that will deliver more intelligent search results and deeper business content, including photos, reviews and videos; as well as improved print yellow pages products resized and reformatted for enhanced readability and reduced paper waste.

“With these changes, we are taking the necessary steps to transform Dex into a leaner, nimbler and more competitive organization,” said Joe Walsh, president and chief executive officer. “Through a combination of cost reductions, product and productivity improvements, we are positioning the company to be the leading digital marketing provider for small and medium-sized businesses.”

The redesign of the company’s search portals, DexKnows.com® and Superpages.com®, will be seen in the first quarter of 2015. Redesigned print directories with attractive new covers and larger interior text will launch in the second quarter of 2015.

¹ On a net debt to adjusted EBITDA basis, before one-time expenses.

About Dex Media

Dex Media (DXM) offers integrated marketing solutions that deliver measurable results. As the marketing department for more than 500,000 small and medium-sized businesses across the U.S., Dex Media helps them Get Found, Get Chosen and Get Talked About. The company’s widely used consumer services include the DexKnows.com® and Superpages.com® search portals and applications as well as local print directories. For more information, visit www.DexMedia.com.

Forward-Looking Statements

Some statements included in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Statements that include the words “may,” “will,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “preliminary,” “intend,” “plan,” “project,” “outlook” and similar statements of a future or forward-looking nature identify forward-looking statements. You should not place undue reliance on these statements, as they are not guarantees of future performance. Forward-looking statements address matters that involve risks and uncertainties. Accordingly, there are or will be important factors that could cause our actual results to differ materially from those indicated in these statements, including among others, whether we will be able to implement the corporate restructuring as planned, whether the expected amount of the costs associated with the corporate restructuring will exceed our expectations and whether we will be able to realize the anticipated benefits in the amounts and at the times expected from the corporate restructuring. We believe that these factors include, but are not limited to, the risks related to the following: our inability to provide assurance for the long-term continued viability of our business; failure to comply with the financial covenants and other restrictive covenants in our credit facilities; limitations on our operating and strategic flexibility and the ability to operate our business, finance our capital needs or expand business strategies under the terms of our credit facilities; limited access to capital markets and increased borrowing costs resulting from our leveraged capital structure and debt ratings; changes in our credit rating; changes in our operating performance; reduced advertising spending and increased contract cancellations by our clients, which causes reduced revenue; declining use of print yellow page directories by consumers; our ability to collect trade receivables from clients to whom we extend credit; credit risk associated with our reliance on small and medium sized businesses as clients; our ability to anticipate or respond to changes in technology and user preferences; our ability to maintain agreements with major Internet search and local media companies; competition from other yellow page directory publishers and other traditional and new media including increased competition from existing and emerging digital technologies; changes in the availability and cost of paper and other raw materials used to print our directories; our reliance on third-party providers for printing, publishing and distribution services; our ability to attract and retain qualified key personnel; our ability to maintain good relations with our unionized employees; changes in labor, business, political and economic conditions; changes in governmental regulations and policies and actions of federal, state and local municipalities impacting our businesses; the outcome of pending or future litigation and other claims; the risk that anticipated cost savings, growth opportunities and other financial and operating benefits as a result of the merger of Dex One and SuperMedia may not be realized or may take longer to realize than expected; and other events beyond our control that may result in unexpected adverse operating results.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in the periodic and other reports we file with the Securities and Exchange Commission, including the information in “Item 1A. Risk Factors” in Part I of our Annual Report on Form 10-K for the year ended Dec. 31, 2013. All forward-looking statements included in this release are expressly qualified in their entirety by the foregoing cautionary statements. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(RDUS) Presents RAD1901 Data at 2014 San Antonio Breast Cancer Symposium

WALTHAM, Mass., Dec. 11, 2014 — Radius Health, Inc. (Nasdaq:RDUS) announced today that it presented data from a Phase 1 clinical study on estrogen receptor engagement by the investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD), in a poster presentation at the 2014 San Antonio Breast Cancer Symposium (SABCS).

Details of the poster presentation at SABCS are as follows:

Title: RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study

Session/Poster: Poster Session 3; Poster OT2-1-10

Location: Halls A-B (Henry B. Gonzalez Convention Center)

Date and Time: Thursday December 11, 2014; 5:00 – 7:00 pm CST

Presenter: Gary Hattersley, PhD, Chief Scientific Officer

Despite advances in the treatment of metastatic breast cancer through modulation of estrogen receptor (ER) activity, after initial efficacy, the use of hormonal therapies is frequently followed by the development of de novo or acquired endocrine resistance. Therefore, research is being conducted on possible new agents that might be able to overcome endocrine resistance. One potential mechanism by which this might be achieved is through degradation of the estrogen receptor and thereby elimination of estrogen receptor mediated signaling.

RAD1901 is an investigational, non-steroidal small molecule that is designed to selectively bind and degrade the ER and is currently being evaluated for the potential treatment of metastatic breast cancer. In preclinical models thus far, RAD1901 has shown good tissue selectivity, does not appear to stimulate the uterine endometrium, and appears to protect against bone loss in an ovariectomy-induced osteopenia rat model. In addition, we believe that RAD1901 has the ability to cross the blood-brain barrier. In vitro, treatment of tamoxifen-sensitive and resistant human breast cancer cell lines with the investigational drug RAD1901 resulted in degradation of the ER and inhibition of both basal and estradiol-stimulated proliferation. The poster includes preclinical data indicating that increasing doses of RAD1901 potently induced tumor regression. Tamoxifen and fulvestrant were the comparator drugs in this study.

The poster also includes data from the Phase 1 study where 18F-estradiol positron emission tomography (FES-PET) was used to provide a pharmacodynamic assessment of estrogen receptor engagement/turnover. Following 6-days of daily treatment with the investigational drug RAD1901 at 200mg and 500mg doses, a complete suppression of FES-PET signal was observed, with standardized uptake values (SUV) comparable to background tissues. To date, the maximum tolerated dose of RAD1901 has not been determined.

The potential clinical significance, if any, of the data presented in the poster is currently unknown and must be evaluated further as the development program for the investigational drug RAD1901 continues.

About The Investigational Drug RAD1901

In June 2014, Radius initiated a Phase 1 MTD study in healthy volunteers with the investigational drug RAD1901, a SERD being developed for the potential treatment of metastatic breast cancer, including breast cancer brain metastases (“BCBM”). The study is designed to evaluate the tolerability, safety, and pharmacokinetics of RAD1901, and also to use 18F-fluroestradiol positron emission tomography to provide a pharmacodynamic assessment of estrogen receptor turnover following RAD1901 treatment. Levels of RAD1901 in cerebrospinal fluid samples taken from the study subjects will be measured to confirm that RAD1901 has crossed the blood brain barrier.

Radius is progressing development of the investigational drug RAD1901 for the potential treatment of metastatic breast cancer. Currently, our Phase 1b metastatic breast cancer trial is undergoing institutional review board review and after approval Radius will post the trial on www.clinicaltrials.gov. We are in discussions with the European Organization for the Research and Treatment of Cancer (EORTC) to finalize the protocol design for the initiation of a European Phase1b trial. We anticipate initiation of these trials following regulatory review and upon institutional review board approval.

Radius also is developing the investigational drug RAD1901 for potential use as a selective estrogen receptor modulator, or SERM, for the treatment of vasomotor symptoms. In a Phase 2 proof of concept study, RAD1901 at lower doses demonstrated a reduction in the frequency and severity of moderate and severe hot flashes. We anticipate initiating a Phase2b trial for the treatment of vasomotor symptoms in 2H2015.

About Radius Health

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius’ lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the potential clinical significance of the data presented in the poster presentation at SABCS, the ability of RAD1901 to cross the blood-brain barrier and the timing of the initiation of clinical trials of RAD1901.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval or be successfully commercialized; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD-1901 and/or RAD-140; our or our licensors’ inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties’ rights; risks related to employees’ disclosure of former employers’ trade secrets; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2014, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Investor Relations
         Barbara Ryan
         FTI Consulting
         Managing Director
         212-850-5679
         Barbara.Ryan@fticonsulting.com

         Media Relations
         Kimberly Ha
         FTI Consulting
         Senior Director
         212-850-5612
         Kimberly.Ha@fticonsulting.com

(NVEE) Awarded $2 Million Contract by San Diego County Regional Airport Authority

(CYRN) & Bangcle to Power Threat Detection for 500 Million Mobile Phone Users

World’s Largest Mobile Application Security Provider to Deploy CYREN Security Technology

MCLEAN, Va., Dec. 10, 2014  — CYREN (NASDAQ: CYRN) and China-based Bangcle, the world’s largest mobile application security provider, today announced that Bangcle will deploy CYREN’s embedded technology to protect mobile applications against today’s latest threats.

Bangcle helps developers guard their apps against malicious code, tampering and pirating while also protecting private customer account information. By the end of November, 400,000 mobile applications have adopted the Bangcle security app shield, which covers 500 million mobile phones globally.

Bangcle’s users will benefit from CYREN Embedded Antivirus as well as CYREN Mobile Security for Android, which delivers the most reliable and proven tool available today to combat increasing malware and other web-borne threats – creating a clear differentiator to help further bolster revenues.

Offering a completely seamless experience, CYREN arms Bangcle customers with a mobile security solution featuring one of the lowest software footprints in the industry. With a modular design for mobile environments, CYREN’s easily integrated technology provides industry-leading performance through ultra-low processing bandwidth consumption, low memory usage, and low storage requirements.

“We chose CYREN’s antivirus technology because our evaluation proved it offered an impressively high detection rate while consuming very little bandwidth,” said Tom Kan, CEO at Bangcle. “Additionally, CYREN offered superior technical support and a level of customer service that not only provides peace of mind for our teams, but those of our users as well.”

“The partnership with Bangcle is one of our latest in Asia – a region that continues to provide a significant number of growth opportunities for CYREN’s embedded business,” said Lior Samuelson, CEO and Chairman of the Board at CYREN. “Bangcle’s selection of CYREN technology underscores our level of commitment to our global network of partners.”

About Bangcle
Bangcle is the world’s largest mobile application security provider. Through its leading technology, Bangcle is committed to providing reliable products and services, and establishing the safe mobile application ecosystem for government, enterprise, developers and consumers. For more information on Bangcle, visit www.secneo.com.

About CYREN
CYREN is a leading provider of cloud-based cybersecurity solutions that deliver powerful protection through global data intelligence. Regardless of the device or its location, CYREN’s easily deployed web, email, and anti-malware products deliver uncompromising protection in both embedded and Security as a Service (SecaaS) deployments. Organizations rely on CYREN’s cloud-based threat detection and proactive security analytics to provide up-to-date spam classifications, URL categorization and malware detection services. The CYREN GlobalView Cloud Platform leverages Recurrent Pattern Detection™ technologies to protect more than 550 million users in 190 countries. CYREN is traded on the NASDAQ Capital Market and the Tel Aviv Stock Exchange (TASE) under the trading symbol “CYRN.” Visit the CYREN GlobalView Security Center or go to www.CYREN.com.

Blog: blog.cyren.com
Facebook: www.facebook.com/CyrenWeb
LinkedIn: www.linkedin.com/company/cyren
Twitter: twitter.com/CyrenInc

© 2014 CYREN Ltd. CYREN and GlobalView are trademarks of CYREN Ltd. Other company and product names may be trademarks of their respective owners.

U.S. Investor Contact:
Garth Russell
KCSA
212.896.1250
grussell@kcsa.com

Israel Investor Relations Contact:
Iris Lubitch
EffectiveIR
+972.54.2528007
iris@FinCom.co.il

CYREN Company Contact:
Mike Myshrall, CFO
CYREN
703.760.3320
mike.myshrall@cyren.com

CYREN Media Contact:
Matthew Zintel
Zintel Public Relations
281.444.1590
matthew.zintel@zintelpr.com

Bangcle Company Contact:
Odin Liu, VP
+86 1062660308
Odin.liu@bangcle.com

Bangcle Media Contact:
Jia Zhao
+086 1062660308
Jia.zhao@bangcle.com

(AKER) Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China

THOROFARE, N.J., Dec. 10, 2014  — Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the “Company”), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the “Order”) valued at US$1,000,000 from NovoTek Therapeutics Inc. (“NovoTek”) to supply PIFA Heparin PF4/Rapid Assay products in Mainland China (“China”).

NovoTek, a Beijing‐based pharmaceutical and medical device business development company, holds the exclusive sales and marketing rights for the Company’s PIFA Heparin/PF4 Rapid Assay products in China. The Company expects to deliver the Order by December 31, 2014.

PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 remain the only US FDA-cleared rapid manual assays that quickly determine if a patient being treated with the blood thinner heparin may be developing a drug allergy. This clinical syndrome known as heparin‐induced thrombocytopenia (“HIT”) reverses the heparin’s intended therapeutic effect and transforms it into a clotting agent. Patients suffering HIT are at risk of developing limb- and life-threatening complications, so the timely test result provided by the Company’s Heparin/PF4 devices is paramount to effective, clinical decision making. In the U.S. alone, approximately 12 million patients are exposed to heparin annually and 1% to 5% of those patients receive a HIT diagnosis. The largest at-risk populations are patients undergoing major cardiac or orthopedic surgical procedures.

“We believe China can be a very significant market for the Company’s PIFA Heparin/PF4 Rapid Assay products,” said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. “Unlike in the U.S. where we are seeking to disrupt a pre-existing, slow, expensive, laboratory-based testing method for heparin platelet factor 4 antibodies, there is, as far as we are aware, no competing test in China,” continued Dr. Akers. “We have been working with NovoTek for two years to advance the regulatory approval process required to launch these tests into China. We are delighted that Akers’ tests will be the first approved diagnostic assay in China to assist in the diagnosis of the allergy to the widely used blood-thinner, heparin.”

“China’s healthcare system is improving and the need for reliable and timely diagnosis is becoming increasingly recognized,” continued Dr. Akers. “With China’s economy growing, we believe it to be the second biggest potential market in the world for our PIFA Heparin/PF4 Rapid Assay products. With no competing test of which are aware, Akers is poised to establish its products as the gold standard,” said Dr. Akers.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

ABOUT NOVOTEK THERAPEUTICS INC.

NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and is in charge of all international business. To date, NovoTek Group has grown to seven subsidiary companies focused on pharmaceutical marketing, medical and IVD products marketing, and contract research services. NovoTek has its own preclinical research facility, clinical trial and regulatory teams, and more than 600 sales representatives (500 for pharmaceuticals and 100 for medical devices) across China. NovoTek has more than 800 employees and more than 10 local branches nationwide. www.novotekchina.com

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information:
         Akers Biosciences, Inc.
         Raymond F. Akers, Jr. PhD
         Executive Chairman of the Board
         Tel. +1 856 848 8698

         RedChip Companies, Inc. (US Investor Relations)
         Jon Cunningham
         Tel. +1 407 644 4256 x107

         finnCap (UK Nominated Adviser and Broker)
         Geoff Nash / Scott Mathieson (Corporate Finance)
         Steve Norcross (Broking)
         Tel: +44 (0)20 7220 0500

         Vigo Communications (UK Investor Relations)
         Ben Simons / Alexandra Roper
         Tel. +44 (0)20 7016 9570
         akers@vigocomms.com

(SOFO) and Lanyon to Present Live Webinar: The Attendee Journey

Mediasite Events by Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted leader for video creation and management solutions, is partnering with Lanyon to present a live webinar, “The Attendee Journey: Leveraging Technology Before, During and After Your Event.”

Register for the free, Dec. 16 webinar at www.sonicfoundry.com/LanyonWebinar.

Lanyon is the leader in providing cloud-based software for meetings, events and travel programs that enables event and marketing professionals to create and manage smarter meetings and events. Lanyon pairs Sonic Foundry’s Mediasite Events webcasting services, which deliver live and on-demand streaming to remote audiences on any device, with its conference management solutions. This enables Lanyon’s customers to deliver a seamless, engaged experience for attendees in-person and online.

The live webinar via Mediasite, presented by Kevin Iwamoto, VP of Industry Strategy at Lanyon, and Donny Neufuss of Mediasite Events, will discuss the latest trends in event design and meeting technology.

Since the spring of 2013, Lanyon captured for its customers more than 2,700 presentations via Mediasite that garnered over 28,000 viewers. That’s more than 5,600 hours of content that is now available on-demand.

“Data shows event attendees are expecting more and more from their event technology. During our webinar, we’ll share what meeting planners should be looking for and why partnering with premier solutions like Mediasite Events can make all the difference in executing a successful event,” Iwamoto said.

Mediasite Events is a leading global provider of live and on-demand webcasting for hybrid events and high-profile meetings, supplying turnkey streaming solutions for about 700 events annually. The group works with Fortune 500 corporations, university associations, sporting events and charitable organizations to produce successful, high-quality online experiences that score rave reviews and achieve event goals.

About Lanyon

Lanyon is the leading provider of cloud-based software for managing corporate meetings, events, and travel programs. From a one-to-one sales meeting, employee training or a large flagship customer conference, Lanyon’s unmatched software and the data it provides helps thousands of organizations and hotels around the world to better engage their customers, reduce costs and grow revenue. Visit www.lanyon.com for more details.

About Sonic Foundry®, Inc.

Sonic Foundry (NASDAQ: SOFO) is the trusted leader for video capture, management and webcasting solutions in education, business and government. The patented Mediasite Enterprise Video Platform transforms communications, training, education and events for more than 3,000 customers in over 60 countries. The company empowers organizations to reach everyone through the power of video; accelerating knowledge-sharing, preserving valuable content, building stronger teams and getting results.

© 2014 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

Sonic Foundry, Inc.
Press Contacts:
Tammy Jackson
608.770.9052
tammy@sonicfoundry.com
or
Nicole Wise
608.237.8678
nicolew@sonicfoundry.com

(ABIO) Announces Management Transitions

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.

Patrick Wheeler, ARCA’s Chief Financial Officer, has notified ARCA of his intent to leave the company in order to pursue other career opportunities after having served ARCA for 9 years. He will remain with the company through December 31, 2014 to assist in the transition of his responsibilities. Mr. Wheeler joined the company in 2006 and has held financial and senior management positions of increasing responsibility throughout his tenure.

Brian Selby has been promoted to Vice President, Finance and Chief Accounting Officer. He will report to the CEO and be responsible for ARCA’s internal and external financial reporting, including compliance with the rules and regulations of the U.S. Securities and Exchange Commission, and corporate financing activities. Mr. Selby has been the company’s Controller for 7 years and has extensive experience in corporate accounting and finance. Prior to joining ARCA, he worked at several public companies, including Controller for Myogen, Inc. and Controller for Genomica Corporation.

Thomas Keuer has been promoted to Chief Operating Officer. He will report to the CEO and be responsible for pharmaceutical operations, human resources, facilities, and information technology. Mr. Keuer has been the Company’s Executive Vice President, Pharmaceutical Operations for the past 8 years. Prior to joining ARCA, he served in a number of senior leadership positions in the biopharmaceutical industry including SVP of Operations for Insmed, Inc., VP of Engineering for Baxter Healthcare, and VP of Operations for Somatogen, Inc.

“Pat has been a tremendous asset to the Company over the past 9 years, helping shape our strategy, financing and development,” said Michael R. Bristow, President and CEO for ARCA. “We are grateful for his service and contributions and wish him well in all his future endeavors. I am very pleased with the abilities of our people with such longevity within the company to continue the leadership of the organization. I look forward to continuing working with Tom and Brian in their expanded roles. Their industry and professional experience will be valuable as ARCA continues the development of Gencaro as a potential treatment for atrial fibrillation.”

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro^TM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information, please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

(CALA) Presents Novel Pharmacodynamic Assay Data On Glutaminase Inhibition in Tumor

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2014  — Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer agents, today announced results of studies with primary human breast tumors that support glutaminase as a potential target in triple negative breast cancer (TNBC). Using a novel pharmacodynamic assay designed to measure the extent of glutaminase inhibition in a single post-dose tumor biopsy sample, significant glutaminase inhibition was observed following oral administration of CB-839. These data were presented during the San Antonio Breast Cancer Symposium in San Antonio, Texas. Calithera is developing CB-839, a potent, selective and orally bioavailable glutaminase inhibitor that is currently in Phase I clinical trials in solid and hematological malignancies.

“Our development of a novel pharmacological assay allows us to directly assess glutaminase inhibition in patients receiving CB-839 from just a single post-dose tumor biopsy, allowing us to get confirmation that CB-839 is reaching the tumor and inhibiting the target,” said Susan Molineaux, Ph.D., President and Chief Executive Officer of Calithera.

The data were presented in a poster titled, “A Novel Pharmacodynamic Assay to Measure Glutaminase Inhibition Following Oral Administration of CB-839 in Triple Negative Breast Cancer Biopsies,” on December 10, 2014 (Abstract #P1-08-07). Potent glutaminase inhibition by CB-839 was demonstrated in primary TNBC tumor lysates as well as in tumors from a TNBC xenograft model. In addition, glutaminase inhibition of 75-84% was observed in tumor biopsy samples from three solid tumor patients enrolled in early dose cohorts of the ongoing phase I clinical trial.

Additional data showed that glutaminase mRNA expression, protein expression, and enzyme activity are all elevated in human TNBC tumors when compared to ER+ breast cancer tumors, or normal breast tissue. In breast cancer cell lines, expression of glutaminase is a biomarker that predicts sensitivity to CB-839.

Two posters will be presented by Calithera’s collaborators. Details for the presentations are as follows:

About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera’s lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.

Forward-Looking Statements

This news release contains forward-looking statements by Calithera that involve risks and uncertainties. Actual results may differ from Calithera’s expectations and important factors that could cause actual results to differ materially. Calithera’s product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, future clinical trials may not show significant glutaminase inhibition following oral administration of CB-839. Furthermore, Calithera’s product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and other risk factors affecting Calithera’s business can be found in Calithera’s Quarterly Report on Form 10-Q for the period ended September 30, 2014 and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

CONTACT: Jennifer McNealey
         ir@Calithera.com
         650-870-1071

(MDWD) to Present at Oppenheimer 25th Annual Healthcare Conference

MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25^th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11^th at 3:20 p.m. Eastern time.

Mr. Cohen’s presentation will broadcast live and can be accessed by visiting the investors section of the company’s website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

(ATNM) Scientific Board Endorses, Supports Iomab-B Phase 3 Clinical Trial Dev Program

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Actinium’s Iomab-B With the Potential to Change the Way Relapsed and Refractory Acute Myeloid Leukemia (AML) in Older Patients Is Treated

(EXXI) to Present at CapitalOne 2014 Securities Energy Conference

HOUSTON, Dec. 9, 2014  — Energy XXI (Nasdaq:EXXI) (AIM:EXXI) today announced Chairman, President and Chief Executive Officer John Schiller will present at the CapitalOne 2014 Securities Energy Conference in New Orleans on Thursday, Dec. 11, 2014 at 1:40 p.m. Central Time.

Information regarding webcasting will be available on the Energy XXI homepage (www.EnergyXXI.com) in the Investor Relations, Events & Presentations section.

About the Company

Energy XXI is an independent oil and natural gas exploration and production company whose growth strategy emphasizes acquisitions, enhanced by its value-added organic drilling program. The company’s properties are located in the U.S. Gulf of Mexico waters and the Gulf Coast onshore.  Cantor Fitzgerald Europe is Energy XXI’s listing broker in the United Kingdom.  To learn more, visit the Energy XXI website at www.EnergyXXI.com.

CONTACT: ENQUIRIES OF THE COMPANY

         Energy XXI
         Greg Smith
         Vice President, Investor Relations
         713-351-3149
         gsmith@energyxxi.com

         Cantor Fitzgerald Europe
         Nominated Adviser: David Porter, Rick Thompson
         Corporate Broking: Richard Redmayne
         Tel: +44 (0) 20 7894 7000

         Pelham Bell Pottinger
         James Henderson
         jhenderson@pelhambellpottinger.co.uk
         Mark Antelme
         mantelme@pelhambellpottinger.co.uk
         +44 (0) 20 7861 3232

(CGIX) to Receive $530,000 Through New Jersey Technology Business Tax Program

RUTHERFORD, N.J., Dec. 9, 2014  — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.

The program, which is sponsored by the New Jersey Economic Development Authority (EDA), provides up to $60 million each year to eligible New Jersey-based technology and biotechnology companies to support job creation and innovation.

“We want to thank NJEDA for recognizing us once again as a promising and innovative company,” stated Panna Sharma, CEO of Cancer Genetics, Inc. “Receiving $530,000 in non-dilutive financing is a welcome boost to our healthy balance sheet. We are proud to be part of the NJ biotechnology community and appreciate the state’s strong support of growth industries that are essential for job growth and innovation.”

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:

Internet: http://www.cancergenetics.com

Twitter: @Cancer_Genetics

Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Media Relations
         Paul Kuntz
         RedChip Companies, Inc.
         800-733-2447, ext. 105
         paul@redchip.com

         Investor Relations
         Michael Rice
         LifeSci Advisors, LLC
         646-597-6997

(NRCIB) New Solution Enables Healthcare Organizations to Publish Physician Reviews Online

National Research Corporation acquires Digital Assent to launch solution that gives healthcare organizations control over online physician reputation

LINCOLN, NEB., Dec. 9, 2014  — National Research Corporation announced today the acquisition of Digital Assent and launch of its Reputation solution, which enables healthcare organizations to collect, display, and syndicate authentic patient ratings and reviews across owned and affiliated websites.

Atlanta-based Digital Assent developed the provider-focused online review system. Andrew Ibbotson, founder and CEO of Digital Assent, shared his optimism about the Reputation solution’s future.

“National Research is a trusted source of healthcare consumer data and thought leadership in the minds of hospital marketers and health system leaders. Because of their comprehensive portfolio of consumer-focused solutions, we knew National Research would be the best partner to guide and support future development of this solution,” Ibbotson said.

The National Research Reputation solution is powered by patient experience data collected from any survey vendor. Publishing doctor ratings and patient comments online increases search traffic and promotes consumer choice of a healthcare organization. The solution provides a more accurate picture of a physician’s reputation, with a larger sample size and more positive feedback than can be found on third-party physician rating websites.

Steve Jackson, Group President for National Research said, “The National Research Reputation solution is a powerful tool for healthcare organizations seeking to manage physician reputation, optimize marketing spend, and embrace transparency. We’re excited about how quickly and easily clients can implement the solution and realize a return on investment.”

To learn more, visit www.nationalresearch.com/reputation or see us at the Institute for Healthcare Improvement (IHI) conference, Booth #704 on December 7 – 10 in Orlando, Florida.

About National Research Corporation

For more than 30 years, National Research Corporation (NASDAQ: NRCIA and NRCIB) has been at the forefront of patient-centered care. Today the company’s focus on empowering customer-centric healthcare across the continuum extends patient-centered care to incorporate families, communities, employees, senior housing residents, and other stakeholders.

National Research is dedicated to representing the true voice of patients and other healthcare stakeholders. This integration of cross-continuum metrics and analytics uncovers insights for effective performance improvement, quality measurement, care transitions, and many other factors that impact population health management.

For more information, call 800-388-4264, write to info@nationalresearch.com, or visit www.nationalresearch.com.

CONTACT: Kayla Lounsbery 
         Marketing Manager
         National Research Corporation
         800-388-4264
         klounsbery@nationalresearch.com

(MZOR) Receives Purchase Orders for Three Renaissance® Systems in Asia

Mazor Robotics Ltd. (NASDAQGM: MZOR) (TASE: MZOR), a developer of innovative guidance systems and complementary products, today announced that it received a purchase order for two Renaissance systems from its distribution partner in China, Cicel (Beijing) Science & Technology CO. Ltd., reflecting the first systems sold into the Chinese market following the receipt of the China Food and Drug Administration (CFDA) approval to market the Renaissance system in China, in September 2014.

The Company also received a purchase order for one Renaissance system from its distribution partner in Taiwan, Pinnaclemed CO. Ltd. Subject to certain closing conditions, the system is expected to be installed at a newly opened spine hospital in Taiwan. This is the third system purchase by Pinnaclemed Co. Ltd. and will be the third Renaissance system in Taiwan.

“Entering the Chinese market is a significant achievement for Mazor and expands our growing presence in the fastest growth region for Renaissance outside of the U.S. market. We look forward to working closely with our distribution partner to raise the awareness of Renaissance throughout the country highlighting the benefits of the system to leading healthcare facilities. An order for a third system in Taiwan is encouraging as the two systems currently in use have some of the highest utilization rates demonstrating the degree of surgeon comfort, system performance and patient outcome,” commented Ori Hadomi, Mazor’s Chief Executive Officer.

Today’s announcement was made in accordance with Mazor Robotics’ disclosure policy of announcing system sales that have a strategic impact on the business, such as new markets, academic institutions and national accounts.

About Mazor

Mazor Robotics is dedicated to the development and marketing of innovative surgical guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance®, is a state-of-the-art surgical guidance system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 60,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the installment of Renaissance at a leading hospital in Taiwan,. raising the awareness of the Renaissance throughout China, the benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F issued to the SEC on April 9, 2014 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group
Michael Polyviou, 212-850-6020 (Investors)
mpolyviou@evcgroup.com
Robert Jones, 646-201-5447 (Investors)
bjones@evcgroup.com
David Schemelia, 646-201-5431 (Media)
dave@evcgroup.com

(BLRX) Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference

– Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis –

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that data from the on-going Phase 2a clinical trial of BL-8040 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) were reported at the American Society of Hematology (ASH) meeting, held on December 6-9, 2014, in San Francisco.

Results reported to date in the dose-escalation stage of the Phase 2a study show that, even at the highest dose reached to date (1.25 mg/kg), there were no dose-limiting toxicity events or serious adverse events, nor early discontinuations attributable to BL-8040. Furthermore, BL-8040 triggered substantial mobilization of AML cancer cells from the bone marrow to the peripheral blood, with a median 6-fold increase of AML cells in the blood. This mobilization is crucial for exposing a higher ratio of AML cells to accompanying chemotherapy such as Ara-C. Additional results show that after only two days of BL-8040 monotherapy, there was a median decrease of approximately 70% in the amount of AML cells in the bone marrow, while the levels of normal progenitor cells remained stable. Furthermore, BL-8040 as a monotherapy showed a 3.5-fold increase in cell death (apoptosis) of AML cells, both in the bone marrow and in peripheral blood samples.

Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, stated, “We are very encouraged by the data that we see at this stage of the Phase 2a study for BL-8040, which show substantial mobilization and robust apoptosis, and we hope that we will continue to see a dose response as we test higher doses. The dose escalation stage, which is currently ongoing, is expected to be completed early next year. In addition, we recently added the Mayo Clinic as our fourth world-class site in the U.S., and we plan to open up several additional sites in the U.S. in the next few months. We look forward to reporting results of the escalation stage, and initiating the expansion phase of the trial, in which the optimal dose of BL-8040 will be further assessed for safety as well as efficacy. The full study is expected to be completed in the second half of 2015.”

BioLineRx will host a breakfast for investors and analysts in New York on December 12th to present its 2015 clinical development plan for BL-8040, including the initiation of clinical studies in three new indications. Dr. Jorge Cortes, Distinguished Professor of Leukemia Research at the MD Anderson Cancer Center in Houston, Texas, will deliver the keynote presentation, “Current Developments in the AML Treatment Space.” The event will be webcast and presentation materials will be available on the BioLineRx website.

About BL-8040’s Phase 2 Trial

The Phase 2 trial is a multicenter, open-label study under an IND, conducted at nine clinical sites in the U.S. and Israel, and is designed to evaluate the safety and efficacy of repeated doses of BL-8040 in adult patients with relapsed or refractory AML. The primary endpoints of the study are the safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the drug and an efficacy evaluation, indicated by the extent of mobilization of cancer cells from the bone marrow to the peripheral blood, the level of cancer cell death (apoptosis) and clinical responses.

The study is comprised of two parts – the current dose escalation stage and a subsequent expansion stage at the optimal dose determined during the escalation stage. During the dose escalation stage, trial participants are generally recruited in cohorts of three patients at a time, and the dose is increased for each subsequent cohort depending on the safety and tolerability results of the previous cohort, as confirmed by an independent Data Safety Monitoring Board. To date, there have been no serious adverse events related to BL-8040 up to and including the fourth dosing level in the study of 1.25 mg/kg, with the primary adverse event being a transient reaction at the injection site. The study is currently in the fifth and final dosing level originally planned in the study of 1.5 mg/kg. Due to the fact that BL-8040 was found safe at all doses tested to date, and based on the recommendation of the CAB, the Company intends to add additional cohorts to the current dose escalation stage of the study, in order to determine the optimal dose for the remainder of the study.

About BL-8040

BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia, as well as other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 18 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile at all doses tested and was highly effective in the mobilization of hematopoietic stem cells and white blood cells from the bone marrow to the peripheral blood.

BL-8040 also mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. Importantly, BL-8040 has also demonstrated a direct anti-cancer effect by inducing apoptosis. Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. In addition, the current Phase 2 clinical trial in AML patients has demonstrated robust mobilization and apoptosis of cancer cells. BL-8040 was licensed by BioLineRx from Biokine Therapeutics and was previously developed under the name BKT-140.

About Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. According to the American Cancer Society, approximately 14,500 new cases of AML were diagnosed in the United States in 2013, and the median age of AML patients was 66 years old. The frontline treatment for patients with AML includes systemic combination induction chemotherapy. The median survival for patients receiving induction chemotherapy, which is associated with high mortality, is 6-12 months, with shorter survival for patients over the age of 60 or for those with certain gene or chromosome aberrations. The five-year survival rate for AML is 10-30 percent, due to relapsed or refractory disease associated with standard treatments.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial scheduled for completion in mid-2015; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx’s future expectations, including specifically those related to the development and commercialization of BL-8040, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 17, 2014. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.